Drugs https://doi.org/10.1007/s40265-018-0924-4 ADIS DRUG EVALUATION Emma D. Deeks Springer International Publishing AG, part of Springer Nature 2018 Abstract The ﬁrst-in-class b -adrenoceptor agonist mir- status, although data in men (from a phase 4 study and TM abegron is indicated in the EU (Betmiga ), Japan (Be- phase 3 trial subanalyses) are variable; additional studies in TM tanis ) and several other countries for the management of older and male OAB patients are awaited with interest. overactive bladder (OAB) syndrome. Evidence for its use Although further longer-term efﬁcacy and tolerability data in this setting includes several large phase 3 trials. Com- would be beneﬁcial, current clinical evidence indicates that pared with placebo, oral mirabegron for 12 weeks reduced mirabegron provides an alternative to antimuscarinics for the frequency of micturition and generally also that of the management of OAB in adults, including those for incontinence, with other beneﬁts including reduced whom antimuscarinics have proven unsuitable. urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week Mirabegron: clinical considerations in OAB powered comparison versus solifenacin in patients dissat- isﬁed with antimuscarinic efﬁcacy, mirabegron did not First b -adrenoceptor agonist approved for OAB
Drugs – Springer Journals
Published: Jun 4, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud